Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | DDO | Q99489 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20853134 | 0.81 | DAO (0.49) | DAODDONSD2KDM4EHRH4 | |
| SCHEMBL27923266 | 0.79 | CYP2A6 (0.53) | DAODDOCYP2A6ALDH1A1NPSR1 | |
| SCHEMBL26671161 | 0.78 | CYP2A6 (0.43) | DAOCYP2A6KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL20840621 | 0.78 | DAO (0.53) | DAOCYP2A6KDM4EHRH4ALDH1A1 | |
| SCHEMBL4282939 | 0.78 | DAO (0.53) | DAODDOCYP2A6HRH4 | |
| SCHEMBL6818942 | 0.78 | CYP2A6 (0.52) | DAODDOCYP2A6KDM4EHRH4 | |
| SCHEMBL29955749 | 0.78 | CYP2A6 (0.52) | DAODDOCYP2A6KDM4EHRH4 | |
| SCHEMBL27849723 | 0.78 | CYP2A6 (0.52) | DAODDOCYP2A6KDM4EHRH4 | |
| SCHEMBL20920169 | 0.77 | ALDH1A1 (0.49) | DAOCYP2A6KDM4EHRH4ALDH1A1 | |
| SCHEMBL4071083 | 0.77 | DAO (0.61) | DAODDONSD2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070130702-A1 | Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative | L'OREAL S.A. | 2007-06-14 | — | — | US | claimed |
| US-7204857-B1 | Dyeing method using a specific active methylene compound and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative | L'OREAL S.A. (FR) | 2007-04-17 | — | — | US | claimed |
| US-6635090-B1 | Dyeing method using a specific cationic derivative and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative | L'OREAL, S.A. (FR) | 2003-10-21 | — | — | US | claimed |
| US-6458168-B1 | Hair dyeing method using an aliphatic cationic amine and compound chosen from an aldehyde, a ketone, a quinone, a di-imino-isoindoline, and a 3-aminoisoindolone derivative | L'OREAL S.A. (FR) | 2002-10-01 | — | — | US | claimed |
| US-6451067-B1 | HAIR DYE MIXTURE | L'OREAL S.A. (FR) | 2002-09-17 | — | — | US | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2025-07-15 | — | — | US | disclosed |
| CN-119855589-A | Heterocyclic PAD4 inhibitors | 细胞基因公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2024-05-16 | — | — | US | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY | 2011-11-24 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI1, PADI6 | DAO 711/4885DDO 297/4885CYP2A6 1160/4885 |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | DAO 3686/4885DDO 2897/4885CYP2A6 2661/4885 |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | PADI4, PADI2, PADI1 | DAO 387/4885DDO 252/4885CYP2A6 1259/4885 |
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | DAO 596/4885DDO 191/4885CYP2A6 1880/4885 |
| US-20070130702-A1 | Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative | KRT18, NDUFB5, NDUFB7 | DAO 161/4885DDO 283/4885CYP2A6 799/4885 |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | DAO 596/4885DDO 191/4885CYP2A6 1880/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | DAO 2307/4885DDO 1943/4885CYP2A6 2969/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | DAO 2158/4885DDO 1779/4885CYP2A6 2793/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | DAO 2158/4885DDO 1779/4885CYP2A6 2793/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | DAO 2158/4885DDO 1779/4885CYP2A6 2793/4885 |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | DAO 387/4885DDO 252/4885CYP2A6 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.